Publicaciones (19) Publicaciones de Esperanza Martín Sanchez

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

2021

  1. A dna methylation-based gene signature can predict triple-negative breast cancer diagnosis

    Biomedicines, Vol. 9, Núm. 10

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  3. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  4. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

    Frontiers in Immunology, Vol. 12

  5. Understanding the molecular mechanism of mir-877-3p could provide potential biomarkers and therapeutic targets in squamous cell carcinoma of the cervix

    Cancers, Vol. 13, Núm. 7

2020

  1. ADAM12 is a potential therapeutic target regulated by hypomethylation in triple-negative breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 3

  2. Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix

    International Journal of Molecular Sciences, Vol. 21, Núm. 6

2017

  1. CDH22 hypermethylation is an independent prognostic biomarker in breast cancer

    Clinical Epigenetics, Vol. 9, Núm. 1

  2. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer

    Oncotarget, Vol. 8, Núm. 9, pp. 15789-15801

2016

  1. Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA

    Virchows Archiv, Vol. 469, Núm. 1, pp. 51-59

2015

  1. Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix

    Pathology International, Vol. 65, Núm. 9, pp. 476-485

2014

  1. NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

    Modern Pathology, Vol. 27, Núm. 10, pp. 1331-1337

  2. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases

    PLoS ONE, Vol. 9, Núm. 11

  3. PLCG1 mutations in cutaneous T-cell lymphomas

    Blood, Vol. 123, Núm. 13, pp. 2034-2043

2013

  1. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells

    Clinical Cancer Research, Vol. 19, Núm. 9, pp. 2319-2330

  2. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas

    Haematologica, Vol. 98, Núm. 1, pp. 57-64

2011

  1. HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines

    British Journal of Haematology

2009

  1. Chromosome instability in lymphocytes of children with coeliac disease

    Journal of Pediatric Gastroenterology and Nutrition, Vol. 49, Núm. 1, pp. 143-146